BLTE
USDBelite Bio Inc American Depositary Shares
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$114.150
고가
$114.440
저가
$112.000
거래량
0.08M
기업 기본 정보
시가총액
4.0B
산업
생명공학
국가
United States
거래 통계
평균 거래량
0.07M
거래소
NCM
통화
USD
52주 범위
관련 뉴스
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have
Belite Bio Announces UK's Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
MHRA response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 SAN DIEGO, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage drug
Benchmark Maintains Buy on Belite Bio, Raises Price Target to $132
Benchmark analyst Bruce D. Jackson maintains Belite Bio with a Buy and raises the price target from $80 to $132.
Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal
Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
NMPA's response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), a clinical-stage drug
관련 주식
최신 정보 받기
가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기